Immunovant, Inc. Common Stock
IMVTImmunovant, Inc. is a biotechnology company focused on developing and commercializing therapies for autoimmune diseases and other immune-mediated disorders. The company primarily targets B-cell mediated conditions, aiming to provide innovative treatments through its antibody modulation platform.
Company News
The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I in...
Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibi...
The generalized myasthenia gravis (gMG) market is experiencing significant growth with 8 promising late-stage drug candidates in development. The gMG market across 7 major markets was valued at USD 5.9 billion in 2025 and is projected to grow at 9.1% CAGR through 2036. Key therapies in development include FcRn inhibitors, complement inhibitors, B...
Immunovant reported that its two Phase 3 clinical studies of batoclimab for thyroid eye disease (TED) failed to meet their primary endpoint of ≥2mm proptosis responder rate at Week 24. However, safety results were consistent with previous findings with no new safety signals. The company remains focused on advancing IMVT-1402 in multiple autoimm...
Immunovant reported Q3 2025 financial results with a net loss of $110.6 million. The company's IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis is fully enrolled with topline data expected in H2 2026. A $550 million financing was completed in December 2025, extending cash runway through potential Graves' disea...
